To date, it has been reported that immunotherapy improves survival only in patients with viral HCC compared to non-viral ones, whereas in MASLD-related HCC patients, the blockage of PD-1/PD-L1 signaling is associated with the decreased survival of patients. Here, PDCD1 is linked to hepatocellular carcinoma.